Profile of HIV resistance to antiretrovirals in patients co-infected with hepatitis B virus

Emmanuel Sako Haddison (esakoh@yahoo.ca)
internal medicine, Yaounde 1
September, 2014
 

Abstract

Background: HIV and Hepatitis B virus co-infection is common but the dual activity of some antiretrovirals against these viruses simplified the management. Nevertheless, the development of HIV and HBV resistance complicates the condition. Consequently, we sought to determine the profile of HIV resistance to antiretrovirals in patients co-infected with hepatitis B virus on HAART in Yaoundé.
Methods: Consecutively, HIV patients on HAART were screened for HBsAg and all the HIV/HBV co-infected patients were enrolled, their plasma collected and tested for HIV drug resistance.
Results: Of the 21 HIV/HBV co-infected patients on HAART retained in this study, 81% had HIV virological failure (HIV RNA>1000copies/ml) after a median treatment time of 24 months. HIV drug resistance mutations were observed in 88.2% of the subjects. Mutation M184V/I known to confer high levels of resistance to lamivudine and emtricitabine was observed in 76.5% of our participants. Other frequent HIV resistance mutations seen were K103N, Y181C/I/V, V75I, and M41L.
Conclusions: HIV drug resistance is a major problem in HIV/HBV co-infected patients on HAART in Cameroon, HIV genotypic resistance testing is an essential tool to follow up these patients and preserve our limited treatment regimens.


********************************************************************************************